SkinBioTherapeutics PLC
LSE:SBTX

Watchlist Manager
SkinBioTherapeutics PLC Logo
SkinBioTherapeutics PLC
LSE:SBTX
Watchlist
Price: 15.125 GBX -9.02% Market Closed
Market Cap: 39.1m GBX

Intrinsic Value

The intrinsic value of one SBTX stock under the Base Case scenario is 21.998 GBX. Compared to the current market price of 15.125 GBX, SkinBioTherapeutics PLC is Undervalued by 31%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SBTX Intrinsic Value
21.998 GBX
Undervaluation 31%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
SkinBioTherapeutics PLC

What is Valuation History?
Ask AI Assistant
What other research platforms think about SBTX?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is SBTX valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for SkinBioTherapeutics PLC.

Explain Valuation
Compare SBTX to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about SBTX?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
SkinBioTherapeutics PLC

Current Assets 2.6m
Cash & Short-Term Investments 1.2m
Receivables 501.8k
Other Current Assets 828k
Non-Current Assets 4.7m
PP&E 478.1k
Intangibles 4.3m
Current Liabilities 1.4m
Accounts Payable 723.3k
Other Current Liabilities 708.5k
Non-Current Liabilities 1.4m
Long-Term Debt 976.4k
Other Non-Current Liabilities 400.6k
Efficiency

Free Cash Flow Analysis
SkinBioTherapeutics PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
SkinBioTherapeutics PLC

Revenue
2.7m GBP
Cost of Revenue
-1.2m GBP
Gross Profit
1.5m GBP
Operating Expenses
-4m GBP
Operating Income
-2.6m GBP
Other Expenses
-20.8k GBP
Net Income
-2.6m GBP
Fundamental Scores

SBTX Profitability Score
Profitability Due Diligence

SkinBioTherapeutics PLC's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

ROIC is Increasing
Exceptional Gross Margin
Operating Margin is Increasing
Strong 3Y Average Gross Margin
26/100
Profitability
Score

SkinBioTherapeutics PLC's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

SBTX Solvency Score
Solvency Due Diligence

SkinBioTherapeutics PLC's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Short-Term Solvency
60/100
Solvency
Score

SkinBioTherapeutics PLC's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SBTX Price Targets Summary
SkinBioTherapeutics PLC

Wall Street analysts forecast SBTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SBTX is 29.58 GBX with a low forecast of 29.29 GBX and a high forecast of 30.45 GBX.

Lowest
Price Target
29.29 GBX
94% Upside
Average
Price Target
29.58 GBX
96% Upside
Highest
Price Target
30.45 GBX
101% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

SkinBioTherapeutics PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for SBTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one SBTX stock?

The intrinsic value of one SBTX stock under the Base Case scenario is 21.998 GBX.

Is SBTX stock undervalued or overvalued?

Compared to the current market price of 15.125 GBX, SkinBioTherapeutics PLC is Undervalued by 31%.

Back to Top